Overview

• U.S. biopharma firm's Q1 net loss narrowed yr/yr as R&D expenses declined

• Company completed $175 mln equity financing in April 2026

• Cash position expected to fund operations through 2028, including Phase 3 acne trial data readout

Outlook

• Sagimet expects cash resources to fund operations through 2028, including denifanstat Phase 3 data readout

• Sagimet plans to start Phase 3 denifanstat acne trial in U.S. in second half of 2026

• Company plans to begin Phase 2 TVB-3567 acne trial in second half of 2026, pending Phase 1 results

Result Drivers

• LOWER R&D SPENDING - Q1 net loss narrowed due to a decrease in research and development expenses

• EQUITY FINANCING - $175 mln equity raise in April 2026 bolstered cash position for clinical development

Company press release: ID:nGNX2Y3XCB

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$10.65 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Sagimet Biosciences Inc is $29.00, about 277.1% above its May 11 closing price of $7.69

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.